Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET-UC: JNJ-78934804 in Moderately to Severely Active Ulcerative Colitis
NCT05242484Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
Phase 2, randomised, double-blind trial of guselkumab + golimumab in ulcerative colitis (UC) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical Remission at 48 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
guselkumab + golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05242484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242484.